11 research outputs found

    The C-terminal region of Trypanosoma cruzi MASPs is antigenic and secreted via exovesicles.

    Get PDF
    Trypanosoma cruzi is the etiological agent of Chagas disease, a neglected and emerging tropical disease, endemic to South America and present in non-endemic regions due to human migration. The MASP multigene family is specific to T. cruzi, accounting for 6% of the parasite's genome and plays a key role in immune evasion. A common feature of MASPs is the presence of two conserved regions: an N-terminal region codifying for signal peptide and a C-terminal (C-term) region, which potentially acts as GPI-addition signal peptide. Our aim was the analysis of the presence of an immune response against the MASP C-term region. We found that this region is highly conserved, released via exovesicles (EVs) and has an associated immune response as revealed by epitope affinity mapping, IFA and inhibition of the complement lysis assays. We also demonstrate the presence of a fast IgM response in Balb/c mice infected with T. cruzi. Our results reveal the presence of non-canonical secreted peptides in EVs, which can subsequently be exposed to the immune system with a potential role in evading immune system targets in the parasite

    Altered distribution of peripheral blood memory B cells in humans chronically infected with Trypanosoma cruzi.

    Get PDF
    Numerous abnormalities of the peripheral blood T cell compartment have been reported in human chronic Trypanosoma cruzi infection and related to prolonged antigenic stimulation by persisting parasites. Herein, we measured circulating lymphocytes of various phenotypes based on the differential expression of CD19, CD4, CD27, CD10, IgD, IgM, IgG and CD138 in a total of 48 T. cruzi-infected individuals and 24 healthy controls. Infected individuals had decreased frequencies of CD19+CD27+ cells, which positively correlated with the frequencies of CD4+CD27+ cells. The contraction of CD19+CD27+ cells was comprised of IgG+IgD-, IgM+IgD- and isotype switched IgM-IgD- memory B cells, CD19+CD10+CD27+ B cell precursors and terminally differentiated CD19+CD27+CD138+ plasma cells. Conversely, infected individuals had increased proportions of CD19+IgG+CD27-IgD- memory and CD19+IgM+CD27-IgD+ transitional/naĂŻve B cells. These observations prompted us to assess soluble CD27, a molecule generated by the cleavage of membrane-bound CD27 and used to monitor systemic immune activation. Elevated levels of serum soluble CD27 were observed in infected individuals with Chagas cardiomyopathy, indicating its potentiality as an immunological marker for disease progression in endemic areas. In conclusion, our results demonstrate that chronic T. cruzi infection alters the distribution of various peripheral blood B cell subsets, probably related to the CD4+ T cell deregulation process provoked by the parasite in humans

    Mathematik und Statistik

    No full text

    A panoramic view of the immune response to Trypanosoma cruzi infection

    No full text
    Chagas disease is a complex disorder in which the immunological response developed by the host plays a fundamental role, not only in the clearance of the parasite but also in the inflammatory status observed in specific affected tissues. Chagas disease has two phases, acute and chronic, the latter being established in those cases where treatment with currently available anti-parasitic drugs (Nifurtimox and Benznidazole) is either not applied or not effective. During the chronic phase, the disease may remain without any detectable symptoms for several decades, or progress toward cardiac, digestive, neurological forms, or even a combination of these alterations. The immune response developed in all of these conditions is flowery and comprises humoral and cellular components; however the clearance of the parasite is incomplete due to the multiple mechanisms that T. cruzi deploys in order to perpetuate itself within the host.Here, we make an extensive review of T. cruzi-host immune response interactions with special attention on human models, and also referring to the particular clinical scenario of etiological treatment in Chagas disease.Fil: Acevedo, Gonzalo RaĂșl. Consejo Nacional de Investigaciones CientĂ­ficas y TĂ©cnicas. Instituto de Investigaciones en IngenierĂ­a GenĂ©tica y BiologĂ­a Molecular "Dr. HĂ©ctor N. Torres"; ArgentinaFil: Girard, MagalĂ­ Celeste. Consejo Nacional de Investigaciones CientĂ­ficas y TĂ©cnicas. Instituto de Investigaciones en IngenierĂ­a GenĂ©tica y BiologĂ­a Molecular "Dr. HĂ©ctor N. Torres"; ArgentinaFil: Gomez, Karina Andrea. Consejo Nacional de Investigaciones CientĂ­ficas y TĂ©cnicas. Instituto de Investigaciones en IngenierĂ­a GenĂ©tica y BiologĂ­a Molecular "Dr. HĂ©ctor N. Torres"; Argentin

    Current understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease

    No full text
    corecore